Julie Feder
Director of Finance/CFO bei AURA BIOSCIENCES, INC.
Vermögen: 1 Mio $ am 31.03.2024
Profil
Julie B.
Feder is the Chief Financial Officer at Aura Biosciences, Inc. She previously held the same position at Verastem, Inc. and Clinton Health Access Initiative.
Prior to that, she worked as a Senior Manager at Deloitte & Touche LLP and as Vice President-Internal Audit at Genzyme Corp.
Feder received her undergraduate degree from Sy Syms School of Business.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
AURA BIOSCIENCES INC
0,27% | 01.02.2024 | 134 276 ( 0,27% ) | 1 Mio $ | 31.03.2024 |
Aktive Positionen von Julie Feder
Unternehmen | Position | Beginn |
---|---|---|
AURA BIOSCIENCES, INC. | Director of Finance/CFO | 01.08.2018 |
Ehemalige bekannte Positionen von Julie Feder
Unternehmen | Position | Ende |
---|---|---|
VERASTEM, INC. | Director of Finance/CFO | 01.06.2018 |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Director of Finance/CFO | 01.07.2017 |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Corporate Officer/Principal | 01.01.2008 |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Comptroller/Controller/Auditor | - |
Ausbildung von Julie Feder
Sy Syms School of Business | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
VERASTEM, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Deloitte & Touche LLP
Deloitte & Touche LLP Miscellaneous Commercial ServicesCommercial Services Deloitte & Touche LLP engages in the provision of audit, advisory, financial advisory, tax, and consulting services. The company was founded on March 7, 1995 and is headquartered in New York, NY. | Commercial Services |
Clinton Health Access Initiative
Clinton Health Access Initiative Miscellaneous Commercial ServicesCommercial Services The Clinton Health Access Initiative (CHAI) is a health organization that is dedicated to saving lives, reducing the burden of disease, and strengthening health systems. CHAI is based in Boston, MA, and the CEO of the non-profit company is Deepak Verma. The organization's focus is on improving healthcare in developing countries. | Commercial Services |